Category: Biotech Investment

Transaction Trends 2022: A Good Time to be a Private Company

By AGT | Apr 4, 2023

[1] Contributing Author John Vandermosten, Senior Biotechnology Analyst After a final burst of initial public offerings (IPOs) in early 2021, times have been difficult for life sciences public equities. S&P’s small cap biotech exchange traded fund, the XBI, has declined from about 174 in February 2021 to about 76 today, a near 60% fall. Merger and acquisition (M&A) trends have been… [Read More]

AGT CEO Jeff Galvin

Jeff Galvin Wins Life Sciences Voice Top Industry Leaders Award

By AGT | Mar 16, 2023

Contributing Author: Kathy Fowler American Gene Technologies® CEO and founder Jeff Galvin was awarded the Life Sciences Voice 2023 Top Industry Leaders Award. The annual award recognizes the most dynamic leaders in the life sciences industry, who are making the biggest impact in delivering transformation that is moving the industry forward. Life Sciences Voice lauds these winners as the industry’s… [Read More]

American Gene Technologies Celebrates Another Year of Progress

By AGT | Dec 28, 2022

Contributing Author John Vandermosten, Senior Biotechnology Analyst In 2022, the world was collectively compelled to endure a surge in viral outbreaks, the horror of the Russia-Ukraine war and rampant inflation, which has led many to a state of pessimism. But, the dramatic events of 2022 have overshadowed other, more reassuring news. In contrast to the gloom of this daily news cycle,… [Read More]

ShareTreck Interviews Jeff Galvin on the Future of Medicine

ShareTreck Host Interviews Jeff Galvin on The Future of Medicine

By AGT | Nov 28, 2022

Contributing Author: Kathy Fowler Raj Natarajan, host of ShareTreck, goes behind the scenes with Jeff Galvin, Founder and CEO of American Gene™ in this compelling interview learn how gene therapy works, and what it means for people with deadly diseases, as well as how it will impact the current pharmaceutical landscape. The company is currently in the midst of a… [Read More]

The Future of Gene Therapy

The Future of Gene Therapy

By AGT | Oct 24, 2022

Contributing Author John Vandermosten, Senior Biotechnology Analyst Economies of scale can apply to gene therapy too Gene therapy’s advantage is its ability to modify the genetic cause of disease. The approach has the potential to correct genetic errors, cure genetic disease and fight serious infections using the body’s own machinery. Its capabilities seem almost limitless, as does the cost of recently… [Read More]

2021 IPO & M&A Trends

By AGT | Feb 7, 2022

Contributing Author John Vandermosten, Senior Biotechnology Analyst Transaction Trends 2021: Pandora’s Box 2020 was a tremendous year for Initial Public Offerings (IPOs) where 494 new issues came to market[1], but the achievement was eclipsed in 2021 with an all-time record of 1,058 companies going public.  In healthcare/life sciences, we counted 118 IPOs in 2020, rising to an impressive 147 in 2021. … [Read More]

Top Cell Therapy Approvals and Pipeline / Cell Therapy is More Than CAR T

Top Cell Therapy Approvals and Pipeline / Cell Therapy is More Than CAR T

By AGT | Oct 18, 2021

Contributing Author John Vandermosten, Senior Biotechnology Analyst Cell therapy is the transfer of therapeutic cells to a patient.  It replaces damaged cells or enhances normal cells with modified new ones.[1]  The cells used in the process may be autologous or allogeneic; however, they must be recognized by the immune system in a way that will promote the desired response.  Some cell… [Read More]

FDA Gene Therapy Approvals

By AGT | Aug 25, 2021

Contributing Author John Vandermosten, Senior Biotechnology Analyst Despite the impact of the pandemic and the seemingly solitary focus of the health care machine on addressing SARS-CoV-2, the gene therapy space continued to progress over the last 18 months.  Several new approvals were granted and promising candidates were advanced in clinical trials and submitted to regulatory authorities.  CAR T has dominated recent… [Read More]

What Is Gene Therapy? How It Works In 2-Minutes

By AGT | Mar 31, 2021

Contributing Author: Gina Hagler   Big Picture    Gene therapy, stem cell therapy, CAR-T, cell therapy and gene editing are all forms of genomic medicine1 – an approach to cure and treat human diseases that uses human biology rather than chemical compounds made in the lab. All of these tools are unlocking techniques and therapies with the power to cure… [Read More]

A SPACtacular Way to Go Public

By AGT | Feb 11, 2021

  What Is A SPAC Anyway? 2020 turned out to be a fantastic year for private companies to go public.  In a hot year for initial public offerings (IPOs), one type of IPO called a Special Purpose Acquisition Company or SPAC has stolen the spotlight.  While they have raised billions, SPACs have no revenues, no operations and no products.  But… [Read More]

5 Reasons Gene Therapy Companies are Vital to the Future of Biopharma

By AGT | Jan 20, 2021

Contributing Author: Gina Hagler Pharmaceutical companies have been developing therapies to treat or prevent disease since the end of the 19th century. Chemical compounds are used to create these drugs and medications. The resulting small-molecule drugs – think aspirin – are ingested, metabolized and circulate through the blood. Because it’s not possible to target these drugs, they have a systemic… [Read More]

7 Cell Therapy Companies in Maryland Helping to Revolutionize Drug Discovery: The Latest News

By AGT | Dec 29, 2020

Contributing Author: Gina Hagler Maryland has one of the largest life science clusters in the United States with more than 500 biotech companies. In addition to several state-of-the-art labs, Maryland is home to the NIH in Bethesda. Research opportunities, as well as BS and MS degree programs, are offered at Johns Hopkins in Baltimore and the University of Maryland in College… [Read More]

Subscribe to Our Newsletter

Subscribe to our newsletter to keep up to date with all the latest news about AGT!

Follow AGT on Social Media